Emerging concepts in the diagnosis and management of metabolically associated steatotic liver disease

Oct 12, 2025Current opinion in endocrinology, diabetes, and obesity

New ideas in diagnosing and treating fatty liver disease linked to metabolism

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Approximately one-third of the population is impacted by MASLD, highlighting the need for earlier diagnosis and effective treatment strategies.

Recent advancements emphasize noninvasive diagnostic methods, moving away from invasive biopsy.
Serum biomarkers like CK-18 and FGF21, along with imaging techniques such as MRI-PDFF and US-FLI, are key to early detection.
Artificial intelligence and machine learning models may enhance risk stratification for MASLD and MASH.
Multiomics approaches, including metabolomics and lipidomics, could aid in identifying disease-specific patterns.
Emerging therapies such as THR β agonists and GLP-1 receptor agonists show potential in reducing liver fat and fibrosis.

AI simplified

PURPOSE OF REVIEW: Given the global rise of MASLD, which impacts approximately one-third of the population, there is a need for earlier diagnosis and effective treatment strategies to avoid long-term hepatic cardiovascular and renal complications. This review summarizes the recent advances in noninvasive diagnosis and new pharmacological agents approved for MASLD.

RECENT FINDINGS: The main step forward in diagnostics is a step away from invasive biopsy and emphasis on noninvasive methods including serum biomarkers (e.g. CK-18 and FGF21), imaging (e.g. MRI-PDFF and US-FLI), combination of the two and use of artificial intelligence and machine learning models, for early detection and risk stratification of MASLD and MASH. Multiomics approaches, such as metabolomics and lipidomics, reveal disease-specific signatures, and may help with phenotypic classification of MASLD. Personalized management for MASLD include gut microbiota modulation and point-of-care devices for rapid diagnosis. Novel therapies include THR β agonists, GLP-1/dual GLP-1/GIP agonists, FXR agonists and FGF analogues, which show promise in reducing hepatic fat and fibrosis.

SUMMARY: These findings enable earlier MASLD diagnosis and tailored interventions, improving clinical outcomes in primary care and resource-limited settings. Future research should focus on validating cost-effective tools, and developing combination therapies to address the multifaceted nature of MASLD.

Full Text

Full text is available at the source.

View full text ↗

Emerging concepts in the diagnosis and management of metabolically associated steatotic liver disease

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief